Bendamustin. Neue Wege bei Lymphomen und soliden Tumoren. Bendamustin-Workshop, Dresden, 2. September 2000
T. Kühn, Christoph Kahl(Klinikum Magdeburg), B. Schymura, U. Winkler, Rhayun Song(Chungnam National University), T. Wiegel, Marcus Groettrup(University of Konstanz), B. van Wegberg, Christoph Hürny(International Breast Cancer Study Group), P. Robben-Bathe, U. Aydemir, E. Dühmke, L. Edler, Peter Heusser, K. Mross, S. Pampallona, Stefan Schwartz(Charité - Universitätsmedizin Berlin), V. Diehl, C. Scheid, R. Kreienberg(Heidelberg University), Joachim Baumgart(Medac (Germany)), Jens Dannull(University of St.Gallen), W. Hinkelbein, Dirk Bottke, S. Helwig, Hermann Schulz(University of Freiburg), S. Sehlen, A. Engert, W.E. Berdel, Clemens Unger(AstraZeneca (United Kingdom)), R. Hartenstein, Michael Fuchs(Virginia Commonwealth University), G. Schaller, H. H. Fiebig, Angela M. Krackhardt(German Cancer Research Center), Daniel Ackermann, Jan Oliver Staak, H. Hollenhorst, E. von Rohr, A. Schulz, Norbert Bornfeld(University of Duisburg-Essen), D. Söhngen, KM Kreusel, T. Cerny, Nicole von Steinbüchel(University of Göttingen), Jürg Bernhard(International Breast Cancer Study Group), R. Abelius, E. Thiel, Claudia Bausewein(Ludwig-Maximilians-Universität München)
Cited by 0
Related Papers
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry
|Nature Communications|2016|727